Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942290 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
A Phase 1 study of Myelodysplastic Syndromes (MDS), sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT02942290 is a Phase 1 study of Myelodysplastic Syndromes (MDS) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 129 participants, below the 177-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02942290, a Phase 1 study of Myelodysplastic Syndromes (MDS), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
Study Locations (20)
New South Wales
- Concord Repatriation General Hospital /ID# 154958 - Concord
- Duplicate_St. Vincent's Hospital, Darlinghurst /ID# 222846 - Darlinghurst
- St George Hospital /ID# 154954 - Kogarah
- Liverpool Hospital /ID# 222410 - Liverpool
- Calvary Mater Newcastle /ID# 154957 - Waratah
Massachusetts
- Tufts Medical Center /ID# 153672 - Boston
- Dana-Farber Cancer Institute /ID# 152735 - Boston
New York
- Columbia University Medical Center /ID# 153661 - New York
- Weill Cornell Medical College /ID# 155524 - New York
Tennessee
- Tennessee Oncology-Nashville Centennial /ID# 222769 - Nashville
- Vanderbilt University Medical Center /ID# 152738 - Nashville
Arizona
- Duplicate_University of Arizona Cancer Center - North Campus /ID# 154155 - Tucson
Illinois
- The University of Chicago Medical Center /ID# 153673 - Chicago
Maryland
- University of Maryland, Baltimore /ID# 153669 - Baltimore
Missouri
- Washington University-School of Medicine /ID# 153671 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-01-12 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02942290
The ClinicalTrials.gov registry entry for NCT02942290 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (27% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes (MDS) appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT02942290 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New South Wales, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT02942290 about?
NCT02942290 is a clinical study titled "A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)". This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.
What is the current status of trial NCT02942290?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2017-01-12. Estimated completion is 2027-01.
What conditions does trial NCT02942290 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes (MDS).
What interventions are being tested in trial NCT02942290?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT02942290?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02942290 being conducted?
This trial has 20 study locations across Arizona, Illinois, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RECRUITING · Phase 1
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RECRUITING · Phase 3
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.